<VariationArchive VariationID="653792" VariationName="NM_004364.5(CEBPA):c.320del (p.Asp107fs)" VariationType="Deletion" Accession="VCV000653792" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-20" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="647918" VariationID="653792">
      <GeneList>
        <Gene Symbol="CEBPA" FullName="CCAAT enhancer binding protein alpha" GeneID="1050" HGNC_ID="HGNC:1833" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.11</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="33299934" stop="33302534" display_start="33299934" display_stop="33302534" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="33790839" stop="33793429" display_start="33790839" display_stop="33793429" Strand="-" />
          </Location>
          <OMIM>116897</OMIM>
          <Haploinsufficiency last_evaluated="2022-06-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CEBPA">No evidence available</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-06-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CEBPA">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_004364.5(CEBPA):c.320del (p.Asp107fs)</Name>
      <CanonicalSPDI>NC_000019.10:33302094:T:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19q13.11</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="33302095" stop="33302095" display_start="33302095" display_stop="33302095" variantLength="1" positionVCF="33302094" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="33793001" stop="33793001" display_start="33793001" display_stop="33793001" variantLength="1" positionVCF="33793000" referenceAlleleVCF="GT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>D107fs</ProteinChange>
      <ProteinChange>D93fs</ProteinChange>
      <ProteinChange>D142fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001285829.2" sequenceAccession="NM_001285829" sequenceVersion="2" change="c.-38del">
            <Expression>NM_001285829.2:c.-38del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287424.2" sequenceAccession="NM_001287424" sequenceVersion="2" change="c.425del">
            <Expression>NM_001287424.2:c.425del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274353.1" sequenceAccession="NP_001274353" sequenceVersion="1" change="p.Asp142fs">
            <Expression>NP_001274353.1:p.Asp142fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001287435.2" sequenceAccession="NM_001287435" sequenceVersion="2" change="c.278del">
            <Expression>NM_001287435.2:c.278del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001274364.1" sequenceAccession="NP_001274364" sequenceVersion="1" change="p.Asp93fs">
            <Expression>NP_001274364.1:p.Asp93fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004364.5" sequenceAccession="NM_004364" sequenceVersion="5" change="c.320del" MANESelect="true">
            <Expression>NM_004364.5:c.320del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004355.2" sequenceAccession="NP_004355" sequenceVersion="2" change="p.Asp107fs">
            <Expression>NP_004355.2:p.Asp107fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.33302095del" Assembly="GRCh38">
            <Expression>NC_000019.10:g.33302095del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012022.1" sequenceAccession="NG_012022" sequenceVersion="1" change="g.5430del">
            <Expression>NG_012022.1:g.5430del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_456" sequenceAccession="LRG_456">
            <Expression>LRG_456:g.5430del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.33793001del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.33793001del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004364.4" sequenceAccession="NM_004364" sequenceVersion="4" change="c.320delA">
            <Expression>NM_004364.4:c.320delA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1600023511" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004364.5(CEBPA):c.320del (p.Asp107fs) AND Acute myeloid leukemia" Accession="RCV000809619" Version="4">
        <ClassifiedConditionList TraitSetID="6288">
          <ClassifiedCondition DB="MedGen" ID="C0023467">Acute myeloid leukemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-15" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11242107</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26162409</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31867767</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32430494</ID>
        </Citation>
        <DescriptionHistory Dated="2022-05-15">
          <Description>Likely pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="6288" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15736" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Acute myeloid leukemia</ElementValue>
                <XRef ID="HP:0004808" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0018874" DB="MONDO" />
                <XRef ID="519" DB="Orphanet" />
                <XRef ID="17788007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute myeloid leukemia, adult</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">AML adult</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute myelogenous leukemia</ElementValue>
                <XRef ID="Acute+Myeloid+Leukemia%2C+Adult/204" DB="Genetic Alliance" />
                <XRef ID="HP:0004808" DB="Human Phenotype Ontology" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute non-lymphocytic leukemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acute granulocytic leukemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukemia, acute myeloid, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Leukemia, acute myelogenous, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">AML</ElementValue>
                <XRef ID="GTR000500636" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="601626" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12757" />
                <XRef ID="12757" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism">Constitutively activated FLT3</Attribute>
                <XRef ID="GTR000552464" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20963938</ID>
                <ID Source="BookShelf">NBK47457</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="NCCN, 2011">
                <ID Source="PubMed">22138009</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESMO, 2013">
                <ID Source="PubMed">23970018</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">33226740</ID>
                <ID Source="BookShelf">NBK564234</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">33661592</ID>
                <ID Source="BookShelf">NBK568319</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">34723452</ID>
                <ID Source="BookShelf">NBK574843</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESMO, 2020">
                <ID Source="PubMed">32171751</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/all.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Myeloid Leukemia, 2023</CitationText>
              </Citation>
              <XRef ID="519" DB="Orphanet" />
              <XRef ID="C0023467" DB="MedGen" />
              <XRef ID="D015470" DB="MeSH" />
              <XRef ID="MONDO:0018874" DB="MONDO" />
              <XRef Type="MIM" ID="601626" DB="OMIM" />
              <XRef Type="primary" ID="HP:0004808" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0001914" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0004843" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0005516" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0006724" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0006728" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1843865" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="5479548|MedGen:C0023467" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000949781" DateUpdated="2024-02-20" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11242107</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31867767</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32430494</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11242107</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26162409</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">11242107</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the region of the CEBPA protein between codon 1 and 120. Other variants in this region have been observed in individuals with autosomal dominant CEBPA-related conditions (PMID: 11242107, 31867767, 32430494; Invitae), which suggests that this may be a clinically significant region of the protein. This variant disrupts the production of the full length isoform (p42) of the CEBPA protein, which results in the preferential usage of an alternate downstream in-frame methionine at codon 120. Translation starting from this methionine results in a 30 kDa N-terminal truncated isoform of CEBPA that lacks the TAD1 domain, and has been shown to abrogate CEBPA function by acting as a dominant-negative allele (PMID: 11242107, 26162409, 11242107). While functional studies have not been performed to directly test the effect of this variant on CEBPA protein function, this suggests that disruption of this region of the protein is causative of disease. ClinVar contains an entry for this variant (Variation ID: 653792). This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asp107Alafs*53) in the CEBPA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 252 amino acid(s) of the CEBPA protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CEBPA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.33793001del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023467" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1843865" TraitType="Disease" MappingType="XRef" MappingValue="C0023467" MappingRef="MedGen">
        <MedGen CUI="C0023467" Name="Acute myeloid leukemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

